An increased loading dose of ondansetron: A north European, double-blind randomised study in children, comparing 5 mg/m2 with 18 mg/m2

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1744-1748

  Brock, P ^a   Brichard, B ^b   Rechnitzer, C ^c   Langeveld, N E ^d   Lanning, M ^e   Soderhall S ^f   Laurent, C ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g GSK   (Belgium)

Author keywords

5 HT3 receptor antagonist; Cisplatin; Emesis; Highly emetogenic; Ifosfamide; Ondansetron

Indexed keywords

CISPLATIN; IFOSFAMIDE; ONDANSETRON;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030249208     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00157-8     Document Type: Article

References (28)

1. 1. Schmoll H-J. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989, 25 (Suppl. 1), S35-S39.
2. 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990, 322, 816-821.
3. 3. Casteels-Van Daele M, Jaeken J, Van Der Schueren M, et al. Dystonic reactions in children caused by metoclopramide. Arch Dis Child 1970, 45, 130-133.
4. 4. Casteels-Van Daele M. Metoclopramide poisoning in children. Arch Dis Child 1981, 56, 406-407.
5. 5. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983, 25 (Suppl. 1), 35-51.
6. 6. Allen JC, Gralla RJ, Reilly LK, et al. Metoclopramide: dose-related toxicity and preliminary anti-emetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985, 3, 1136-1141.
7. 7. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr 1984, 104, 138-140.
8. 8. Zeltzer L, Le Baron S, Zeltzer PM. Paradoxical effects of prophylactic phenothiazine anti-emetics in children receiving chemotherapy. J Clin Oncol 1984, 2, 930-936.
9. 9. Howrie DL, Felix C, Wollman M, et al. Metoclopramide as an antiemetic agent in paediatric oncology patients. DICP 1986, 20, 122-124.
10. 10. Casteels-Van Daele M, Dobosz-Cyclis R, Van de Casseye W, et al. Refusal of further cancer chemotherapy due to antiemetic drug. Lancet 1984, 1, 57.
11. 11. Brock PR, Bokkerink JPM, Tamminga RYJ, et al. Ondansetron for chemotherapy-induced emesis in children. A Benelux study. Int J Ped Haematol/Oncol 1994, 1, 235-240.
12. 12. Carden PA, Mitchell SL, Waters KD, et al. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. J Clin Oncol 1990, 8, 1531-1535.
13. 3 antagonist ondansetron-an effective outpatient anti-emetic in cancer treatment. Arch Dis Child 1990, 65, 822-825.
14. 14. Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology 1992, 49, 279-285
15. 15. Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol R Coll Radiol 1993, 5, 11-14.
16. 3 antagonist. Bone Marrow Transpl 1991, 7, 431-433.
17. 17. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomised, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992, 10, 1969-1975.
18. 18. Bryson JC, Pritchard JF, Shurin S, et al. Efficacy, pharmacokinetics (PK) and safety of ondansetron (OND) in pediatric chemotherapy patients (PTS). Clin Pharmacol Ther 1991, 49(2), 161 Abs PII-49.
19. 19. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990, 322, 810-816.
20. 20. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985, 3, 1379-1384.
21. 21. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatin-based chemotherapy: effects of anti-emetics. J Clin Pharmacol 1993, 33, 691-697.
22. 22. Brock P. Measurement of urinary 5-hydroxyindolacetic acid in children receiving cisplatin by 24-hour infusion. In Cisplatin Toxicity in Infants and Children. Acta Medica Lovaniensia 102, Ch. 4, Catholic University of Leuven, Belgium, 1994.
23. 23. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991, 27 (Suppl. 1), S9-S11.
24. 24. Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991, 303, 1423-1426.
25. 25. Rath U, Upadhyaya BK, Arechavala E, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993, 50, 168-172.
26. 26. Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991, 338, 487-190.
27. 27. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991, 9, 675-678.
28. 28. Bleiberg H, Autier P, Michaux M. Cost effectiveness analysis of anti-emetic treatment. Supp Care Cancer 1994, 2, 145-149.